Stemline Therapeutics, Inc. (NASDAQ:STML) had its target price raised by HC Wainwright from $34.00 to $38.00 in a research note published on Wednesday morning, MarketBeat reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently issued reports on the company. Cowen and Company reissued a buy rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. ValuEngine cut shares of Stemline Therapeutics from a hold rating to a sell rating in a research note on Thursday, August 10th. BidaskClub raised shares of Stemline Therapeutics from a hold rating to a buy rating in a research note on Wednesday, July 19th. Finally, Zacks Investment Research cut shares of Stemline Therapeutics from a hold rating to a sell rating in a research note on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the stock. Stemline Therapeutics has an average rating of Buy and a consensus target price of $33.40.

Shares of Stemline Therapeutics (NASDAQ:STML) traded up $0.35 on Wednesday, hitting $14.15. The stock had a trading volume of 396,004 shares, compared to its average volume of 380,880. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.18). Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. The business had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.30 million. sell-side analysts expect that Stemline Therapeutics will post -2.62 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Stemline Therapeutics, Inc. (STML) PT Raised to $38.00” was reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/stemline-therapeutics-inc-stml-pt-raised-to-38-00/1680752.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in shares of Stemline Therapeutics by 72.1% in the 1st quarter. FMR LLC now owns 2,538,892 shares of the biopharmaceutical company’s stock valued at $21,708,000 after buying an additional 1,063,457 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Stemline Therapeutics by 4.7% during the 2nd quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock valued at $7,946,000 after purchasing an additional 38,615 shares during the last quarter. AXA lifted its holdings in Stemline Therapeutics by 44.9% during the 2nd quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock valued at $5,789,000 after purchasing an additional 195,022 shares during the last quarter. State Street Corp lifted its holdings in Stemline Therapeutics by 11.3% during the 2nd quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock valued at $3,179,000 after purchasing an additional 35,116 shares during the last quarter. Finally, Columbus Circle Investors lifted its holdings in Stemline Therapeutics by 58.4% during the 2nd quarter. Columbus Circle Investors now owns 340,219 shares of the biopharmaceutical company’s stock valued at $3,130,000 after purchasing an additional 125,403 shares during the last quarter. 48.34% of the stock is owned by institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.